High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors by Rigter, L.S. (Lisanne) et al.
1Cancer  Month 0, 2018
Original Article
High Prevalence of Advanced Colorectal Neoplasia and Serrated 
Polyposis Syndrome in Hodgkin Lymphoma Survivors
Lisanne S. Rigter, PhD1; Manon C. W. Spaander, PhD2; Berthe M. P. Aleman, PhD3; Tanya M. Bisseling, PhD4;  
Leon M. Moons, PhD5; Annemieke Cats, PhD1; Pieternella J. Lugtenburg, PhD6; Cecile P. M. Janus7;  
Eefke J. Petersen, PhD8; Judith M. Roesink, PhD9; Richard W. M. van der Maazen, PhD10; Petur Snaebjornsson, PhD11; 
Prof. Ernst J. Kuipers, PhD2; Prof. Marco J. Bruno, PhD2; Prof. Evelien Dekker, PhD 12; Prof. Gerrit A. Meijer, PhD11;  
Jan Paul de Boer, PhD13; Prof. Flora E. van Leeuwen, PhD14; and Monique E. van Leerdam, PhD1
BACKGROUND: Hodgkin lymphoma (HL) survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have an 
increased risk of colorectal cancer (CRC). This study was aimed at evaluating the prevalence of colorectal neoplasia in HL survivors. 
METHODS: This multicenter cohort study assessed the diagnostic yield of advanced colorectal neoplasia detected by a first surveil-
lance colonoscopy among HL survivors treated with abdominal radiotherapy and/or procarbazine. Advanced colorectal neoplasia 
included advanced adenomas (high-grade dysplasia, ≥25% villous component, or ≥10-mm diameter), advanced serrated lesions 
(dysplasia or ≥10-mm diameter), and CRC. The results were compared with those for a Dutch general population cohort that under-
went a primary screening colonoscopy (1426 asymptomatic individuals 50-75 years old). This study demonstrated the results of a 
predefined interim analysis. RESULTS: A colonoscopy was performed in 101 HL survivors, who were significantly younger (median, 
51 years; interquartile range [IQR], 45-57 years) than the general population controls (median, 60 years; IQR, 55-65 years; P < .001). 
The prevalence of advanced neoplasia was higher in HL survivors than controls (25 of 101 [25%] vs 171 of 1426 [12%]; P < .001). 
Advanced adenomas were detected in 14 of 101 HL survivors (14%) and in 124 of 1426 controls (9%; P = .08). The prevalence of ad-
vanced serrated lesions was higher in HL survivors than controls (12 of 101 [12%] vs 55 of 1426 [4%]; P < .001). Serrated polyposis 
syndrome was present in 6% of HL survivors and absent in controls (P < .001). CONCLUSIONS: HL survivors treated with abdominal 
radiotherapy and/or procarbazine have a high prevalence of advanced colorectal neoplasia. The implementation of a colonoscopy 
surveillance program should be considered. Cancer 2018;0:1-10. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on 
behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, 
the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
The risk of colorectal cancer (CRC) is increased in many cancer survivors, including survivors of Hodgkin lymphoma 
(HL), testicular cancer, Wilms tumors, central nervous system malignancies, and bone cancer.1-8 In HL survivors specif-
ically, the reported relative risks of CRC range from 2 to 7 in comparison with the general population.3-9 This increased 
risk continues up to 40 years after HL treatment and is strongly related to treatment with abdominal radiotherapy 
and/or alkylating agents, mainly procarbazine.3,5,9 A recent population-based study has demonstrated that childhood 
cancer survivors have an excess risk of developing colorectal adenomas in addition to CRC.10 Risk factors for adenomas 
in this cancer survivor population also include abdominopelvic irradiation and procarbazine.
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In Dutch clinical practice, colonoscopy surveillance 
programs exist for several high-risk populations, such as 
patients with familial CRC, Lynch syndrome, and in-
flammatory bowel disease. The efficacy of colonoscopy 
surveillance in these high-risk populations results from 
the early detection of CRC and the removal of prema-
lignant lesions; this leads to reduced CRC incidence and 
improved CRC-related survival rates.11,12
Only 1 recent report has evaluated the yield of 
colonoscopy in childhood cancer survivors since the rec-
ommendation of the US Children’s Oncology Group.13 
After a median interval of 19 years since treatment with 
abdominal radiotherapy, adenomas or serrated lesions 
of any size were detected in 15 of 54 patients (28%).14 
However, in that study, no comparison with the general 
population was made.
Colonoscopy surveillance is not incorporated into 
Dutch guidelines on the management of lymphoma or 
childhood cancer survivors. This is related to the lack of 
knowledge of the natural history and presence of precur-
sor lesions, which may influence surveillance efficacy.15 
Here we report on a predefined interim analysis of a study 
aimed at comparing the diagnostic yields of a first surveil-
lance colonoscopy in HL survivors and a first screening 
colonoscopy in the general population.
MATERIALS AND METHODS
Study Aims
The primary aim of this multicenter cohort study was 
to assess the diagnostic yield of advanced colorectal neo-
plasia detected by a first surveillance colonoscopy among 
HL survivors at increased risk for CRC. Advanced colo-
rectal neoplasia was defined as an advanced adenoma 
(high-grade dysplasia, ≥25% villous component, or 
≥10-mm diameter), an advanced serrated lesion (hyper-
plastic polyp/sessile serrated adenoma with dysplasia or 
≥10-mm diameter), or CRC. This definition of advanced 
colorectal neoplasia slightly differs from our original study 
protocol developed in 201316 because recent literature 
and guidelines acknowledge advanced serrated lesions as 
high-risk lesions for CRC development and have changed 
the definition of advanced neoplasia to also include 
advanced serrated lesions.14,17-19
The results were compared with those for a Dutch 
cohort of 1426 asymptomatic individuals aged 50 to 
75 years who underwent a primary screening colonos-
copy between 2009 and 2010 before implementation 
of the Dutch national fecal immunochemical test–
based screening program.20,21 This cohort was chosen 
because it contained the best comparable data avail-
able, representing the Dutch general population and a 
fairly recent time period of colonoscopies. Data on the 
colonoscopy results of the Dutch national screening 
program are for a fecal immunochemical test–positive 
population, and this reduces comparability. In addition, 
data from other countries lacked detailed information 
on neoplastic lesions or lacked comparability of CRC 
incidence.
The medical ethics committee of the Netherlands 
Cancer Institute approved this study protocol. All 
participating patients provided written informed 
consent. The study was registered at the Dutch Trial 
Registry (ID NTR4961). All authors had access to 
the study data and reviewed and approved the final 
manuscript.
Study Population
HL survivors were invited for study participation at 
4 Dutch study centers (the Netherlands Cancer Institute 
in Amsterdam, the Erasmus MC Cancer Institute in 
Rotterdam, the University Medical Center Utrecht, and 
the Radboud University Medical Center in Nijmegen). 
The inclusion criterion was the treatment of primary 
or recurrent HL by means of any of the following 
regimens:
1. Abdominal radiotherapy consisting of at least para- 
aortic and iliac fields.
2. A cumulative procarbazine dose ≥ 2.8 g/m2 (eg, ≥2 
mechlorethamine, vincristine, procarbazine, and pred-
nisone [MOPP] cycles or ≥4 mechlorethamine, vin-
cristine, procarbazine, prednisone, doxorubicin, 
bleomycin, and vinblastine [MOPP/ABV] cycles).
3. Abdominal radiotherapy (any field or fields) and 
chemotherapy (any regimen).
Additional inclusion criteria were an HL diagnosis at 
the age of 16 to 50 years, survival for at least 8 years 
after HL treatment, a current age of 25 years or older, 
and a life expectancy of 5 years or longer. Patients who 
met 1 of the following criteria were excluded: proctocol-
ectomy, colonoscopy surveillance for other indications, 
ongoing cytotoxic treatment or radiotherapy for malig-
nant disease, coagulopathy (prothrombin time > 50% of 
control and partial thromboplastin time > 50 seconds) 
or anticoagulants (vitamin K antagonists or direct oral 
anticoagulants) that could not be stopped,  comorbidity 
leading to an impaired physical performance (World 
Health Organization [WHO] performance status of 
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3-4), and mental retardation. Patients who underwent 
a colonoscopy in the past 5 years were also excluded, 
whereas patients who underwent a colonoscopy more 
than 5 years ago were not excluded. These patients did 
not have follow-up colonoscopies and thus did not 
have relevant neoplasia for surveillance (eg, a negative 
colonoscopy).
Sample Size Calculation
On the basis of a 9% prevalence of advanced adenomas 
or CRC in the asymptomatic general population, an 
increase to 15% or more in HL survivors was defined as 
a significant change. To detect such a difference with 
80% power, we needed to include at least 259 study 
participants (according to a 2-sided test for 2 inde-
pendent proportions with a 5% significance level). A 
predefined interim analysis was performed after the in-
clusion of 100 participants. Here we report the results 
of this interim analysis.
Study Procedures
All patients were invited for participation by their 
hematologist or radiation oncologist, as previously 
described, and received oral and standard written infor-
mation about the preparation and the colonoscopy.16 
Details on the colonoscopy procedure (including prep-
aration, conscious sedation, quality measure reporting, 
and data registration) were published previously.16 In 
the presence of colorectal neoplasia (adenoma, serrated 
lesion, or CRC), polypectomy was performed or bi-
opsies were taken according to the standard protocol, 
regardless of the endoscopic appearance or size. A rou-
tine histological evaluation of all colorectal neoplasias 
was performed by experienced gastrointestinal patholo-
gists. The endoscopic size of the neoplastic lesion was 
used for analyses except if the microscopic measure-
ment of the pathologist was larger than the endoscopic 
measurement. Follow-up was performed according to 
standard clinical care.
Statistical Analyses
All data were stored and analyzed with SPSS Statistics 
22. Dichotomous or categorical data were compared 
between groups with chi-square tests or Fisher exact tests, 
whereas continuous data were compared with Mann-
Whitney U tests. Univariate and multivariate logistic 
regression was performed to assess odds ratios for colo-
rectal neoplasia associated with patient characteristics, 
including HL treatment.22 The significance level was 
defined as a 2-sided P value ≤ .05.
RESULTS
Colonoscopy Participants
A total of 246 HL survivors were invited for participa-
tion (Fig. 1). Between February 2015 and February 2017, 
101 HL survivors (41%) underwent a colonoscopy. 
Patients had been diagnosed with HL between 1975 
and 2004 at a median age of 25 years (interquartile 
range [IQR], 20-32 years; Table 1). HL treatment in-
cluded both abdominal radiotherapy and procarbazine in 
35% of patients, procarbazine without abdominal radio-
therapy in 50%, and abdominal radiotherapy without 
procarbazine in 15%. The median interval between HL di-
agnosis and colonoscopy was 22 years (IQR, 19-28 years). 
Colonoscopy quality measures are reported in Supporting 
Table 1. The cecal intubation rate was 100%, and only 
1 adverse event was reported (ie, hospitalization for 1 day 
due to abdominal pain after colonoscopy).
HL survivors underwent a colonoscopy at a median 
age of 51 years (IQR, 45-57 years), whereas the median 
age was 60 years (IQR, 55-65 years) for the general pop-
ulation cohort, which hereafter is called the controls 
(P < .001; Table 2). The HL survivors were 56% male 
and 44% female, and these proportions were comparable 
to the distribution in the controls.
Prevalence of Colorectal Neoplasia in HL 
Survivors and the General Population Cohort
A total of 350 neoplastic lesions of any type (adenomas, 
serrated lesions, or CRC) were detected in 101 HL survi-
vors, whereas 1529 were detected in 1426 controls (mean, 
3.5 per HL survivor [standard deviation, 4.9] vs 1.1 per 
control [standard deviation, 1.8]; P < .001). In HL survi-
vors, neoplastic lesions were more frequently located in 
the proximal colon (73% vs 40% in controls) and less 
frequently located in the distal colon (21% vs 31%) and 
in the rectum (7% vs 28%; overall P < .001).
Any type of neoplastic lesion was detected in 72% 
of HL survivors and in 45% of controls (P < .001). The 
prevalence of advanced adenomas was 14% in HL sur-
vivors and 9% in controls (P = .08; Table 2). The prev-
alence of advanced serrated lesions was higher in HL 
survivors than controls (12% vs 4%; P < .001). Six HL 
survivors were diagnosed with serrated polyposis syn-
drome: 5 had at least 5 serrated lesions proximal to the 
sigmoid colon, 2 of which were ≥10 mm in diameter 
(WHO criterion 1), and 1 had 20 serrated lesions or 
more, regardless of size, but they were located through-
out the colorectum (WHO criterion 3).23 In contrast, 
serrated polyposis syndrome was not observed in con-
trols (P < .001).
Original Article
4 Cancer  Month 0, 2018
None of the HL survivors were diagnosed with 
CRC, whereas 0.6% of the controls were (P = .42). The 
prevalence of advanced neoplasia, which was defined as an 
advanced adenoma, an advanced serrated lesion, or CRC, 
was 25% in HL survivors and 12% in controls (P < .001 
[uncorrected for the younger age of HL survivors]).
Difference in Colorectal Neoplasia Prevalence 
in Male and Female HL Survivors
The prevalence of advanced adenomas was higher in 
male HL survivors than male controls (23% vs 10%; 
P = .002), whereas the prevalence of advanced serrated 
lesions was similar in the 2 groups (5% in HL survivors 
vs 4% in controls; P = .64; Fig. 2).
In women, the prevalence of advanced adenomas 
was not significantly different in HL survivors and con-
trols (2% vs 8%; P = .24), whereas the prevalence of ad-
vanced serrated lesions was evidently higher (21% in HL 
survivors vs 4% in controls; P < .001). Serrated polyposis 
syndrome was present in 11% of female HL survivors 
(vs 0% of controls; P < .001).
Prevalence of Colorectal Neoplasia in Different 
Age Groups
When we evaluated study participants aged 50 to 70 years, 
advanced neoplasia was present in 33% of HL survivors 
and in 11% of controls (median age, 56 years [IQR, 
52-60 years] vs 59 years [IQR, 55-64 years]; P < .001).
Figure 1. Flow diagram of the study invitations and participants. *Invitations were accompanied by an information leaflet, which 
included information about CRC in general and the advantages and possible risks of colonoscopy. ABVD indicates doxorubicin, 
bleomycin, vinblastine, and dacarbazine; CRC, colorectal cancer; HL, Hodgkin lymphoma.
Colorectal Neoplasia in HL Survivors/Rigter et al
5Cancer  Month 0, 2018
Because the youngest age of the controls was 50 years, 
we compared 37 HL survivors aged 40 to 49 years with 666 
controls aged 50 to 59 years (Fig. 2). The prevalence of ad-
vanced neoplasia was higher in younger HL survivors than 
older controls (19% vs 9%; P = .045). In 37 HL survivors 
and 666 controls aged 50 to 59 years, the prevalence of ad-
vanced neoplasia was 27% and 9%, respectively (P < .001). 
Advanced neoplasia was more common in 17 HL survivors 
aged 60 to 69 years (47% vs 14% in 665 controls; P < .001).
Prevalence of Colorectal Neoplasia After 
Exposure to Abdominal Radiotherapy and/or 
Procarbazine
The prevalence of advanced neoplasia was more com-
mon in the HL survivors treated with both abdominal 
radiotherapy and procarbazine (n = 35) than controls 
(31% vs 12%; P = .001). In the HL survivors with 
TABLE 1. HL Survivor Characteristics (n = 101)
Characteristic Value
Age at HL treatment, median (IQR), y 25 (20-32)
Age at HL treatment, %
16-25 y 51
26-35 y> 36
36-48 y 13
Time since HL treatment, median (IQR), y 22 (19-28)
Time since HL treatment, %
12-19 y 29
20-29 y 55
30-40 y 17
Year of HL treatment, %
1975-1984 15
1985-1994 50
1995-2004 35
HL stage, %
I 11
II 50
III 21
IV 17
Unknown 2
HL treatment category, %
Abdominal RT + procarbazine 35
Procarbazine 50
Abdominal RT 15
HL radiotherapy, %
No RT 12
Cervical RT only 1
Mantle field only 38
Abdominal RT, %
Para-aortic + iliac + spleen 15
Para-aortic + iliac 4
Para-aortic + spleen 22
Para-aortic only 5
Iliac only 3
Lumbal region only 1
HL chemotherapy, %
No CT 9
MOPPa 20
MOPP/ABV 58
Other with procarbazineb 7
Other without procarbazine 6
Abbreviations: BCVPP, carmustine, cyclophosphamide, vinblastine, procar-
bazine, and prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, 
 cyclophosphamide, vincristine, procarbazine, and prednisone; CT, 
 chemotherapy; HL, Hodgkin lymphoma; IQR, interquartile range; MOPP, 
mechlorethamine, vincristine, procarbazine, and prednisone; MOPP/ABV, 
mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, 
 bleomycin, and vinblastine; MOPP/ABVD, mechlorethamine, vincristine, pro-
carbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine; 
RT, radiotherapy.
aIncluding 2 patients who also received MOPP/ABV.
bIncluding BEACOPP, MOPP/ABVD, and BCVPP.
Some numbers do not add up to 100% due to rounding.
TABLE 2. Patient and Colonoscopy Characteristics 
of HL Survivors and General Population Controls
Characteristic
HL Survivors 
(n = 101)
Controls 
(n = 1426) P
Age, median (IQR), y 51 (45-57) 60 (55-65) <.001
Age, %
<40 y 9 0
40-49 y 37 0
50-59 y 37 47
60-69 y 17 47
≥70 y 1 7
Sex, %
Male 56 51 .28
Female 44 49
Neoplastic lesions in total 
groupsa
No. per patient, median 2 0 <.001
No. per patient, %
0 28 55
≥1 72 45 <.001
Neoplasia detection per 
patient, %
Adenomas
≥1 adenoma 55 29 <.001
≥1 advanced adenomab 14 9 .08
Serrated lesions
≥1 serrated lesion 47 27 <.001
≥1 advanced serrated 
lesionc
12 4 <.001
Serrated polyposis 
syndromed
6 0 <.001
WHO 1 5 0
WHO 3 1 0
Colorectal cancer 0 0.6 .42
Advanced neoplasiae 25 12 <.001
Neoplastic lesions in patients 
aged 50-70 yf
≥1 advanced adenomab 15 8 .09
≥1 advanced serrated lesionc 20 4 <.001
Serrated polyposis 
syndromed
11 0 <.001
Advanced neoplasiae 33 11 <.001
Abbreviations: HL, Hodgkin lymphoma; IQR, interquartile range; WHO, 
World Health Organization.
Chi-square tests or Fisher exact tests were used.
aDefined as adenomas, serrated lesions, or cancer.
bDefined as a conventional adenoma with a ≥10-mm diameter, a ≥25% vil-
lous component, or high-grade dysplasia.
cDefined as a serrated lesion with a ≥10-mm diameter or dysplasia.
dWHO 1 is diagnosed in the presence of 5 serrated lesions proximal to the 
sigmoid, with at least 2 having a ≥10-mm diameter; WHO 3 is diagnosed in 
the presence of 20 serrated lesions in the colorectum, regardless of size.
eDefined as an advanced adenoma, an advanced serrated lesion, or colo-
rectal cancer.
fThe n values were 54 for HL survivors and 1331 for controls.
Some numbers do not add up to 100% due to rounding.
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procarbazine treatment without abdominal radio-
therapy (n = 51), the prevalence of advanced adenomas 
was similar to the prevalence in controls (12% vs 9%; 
P = .45). The prevalence of advanced serrated lesions, 
however, was higher in these HL survivors than con-
trols (10% vs 4%; P = .04). Advanced neoplasia was 
slightly but not significantly more common in these 
HL survivors than controls (20% vs 12%; P = .10). In 
the 15 HL survivors who were treated with abdominal 
radiotherapy without procarbazine, the prevalences of 
advanced adenomas, advanced serrated lesions, and ad-
vanced neoplasia were also high but not significantly 
different from those of controls (13% vs 9% [P = .38], 
13% vs 4% [P = .12], and 27% vs 12% [P = .10], 
respectively).
Logistic Regression Models for 
Colorectal Neoplasia Development in HL 
Survivors and Controls
Other potential risk factors for colorectal neoplasia, in-
cluding the frequency of first-degree relatives with CRC, 
smoking, body mass index, and alcohol use, were simi-
larly present or less frequently present in HL survivors 
versus controls (Supporting Table 2).
A univariate logistic regression model showed that 
HL survivors treated with either abdominal radiotherapy 
or procarbazine had an odds ratio for advanced neoplasia 
of 2.0 (95% confidence interval [CI], 1.1-3.6; P = .03) in 
comparison with controls, whereas HL survivors treated 
with both abdominal radiotherapy and procarbazine 
had an odds ratio for advanced neoplasia of 3.4 (95% 
CI, 1.6-7.0; P = .001; Table 3). In a multivariate model 
(adjusted for age, sex, family history, smoking, and body 
mass index), the odds ratio of advanced neoplasia was 
3.3 (95% CI, 1.6-6.6; P = .001) for HL survivors treated 
with either abdominal radiotherapy or procarbazine and 
5.7 (95% CI, 2.6-12.6; P < .001) for HL survivors treated 
with both abdominal radiotherapy and procarbazine.
DISCUSSION
This is the first study to demonstrate that HL survivors 
have a higher prevalence of advanced colorectal neopla-
sia, particularly advanced serrated lesions and serrated 
polyposis syndrome, than the general population. These 
results, in combination with the existing evidence for an 
increased risk of CRC associated with abdominal radio-
therapy and/or procarbazine, indicate that colonoscopy 
Figure 2. Frequencies of neoplasia detection in subgroups of HL survivors and general population controls. An advanced 
adenoma is defined as an adenoma with a ≥10-mm diameter, a ≥25% villous component, or high-grade dysplasia; an advanced 
serrated lesion is defined as a serrated lesion with a ≥10-mm diameter or dysplasia; and advanced neoplasia is defined as an 
advanced adenoma, an advanced serrated lesion, or colorectal cancer. *There was a significant difference between groups 
(P < .05). HL indicates Hodgkin lymphoma; RT, radiotherapy; SPS, serrated polyposis syndrome.
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surveillance should be considered for HL survivors who 
have received these treatments.3-5,9
We demonstrated an increased prevalence of ad-
vanced colorectal neoplasia in HL survivors between 40 
and 70 years old. True differences in the prevalence of 
neoplasia were underestimated in this study because HL 
survivors had a much lower median age than the gen-
eral population comparison group. Unfortunately, no 
statistical adjustment could be performed to account 
for this age difference because of the lack of data on pri-
mary colonoscopy yields in a young group of average-risk 
individuals.
HL treatment consisting of either abdominal radio-
therapy or procarbazine was associated with an increased 
prevalence of advanced colorectal neoplasia. The largest 
odds ratio for the prevalence of advanced colorectal neo-
plasia was seen in HL survivors whose treatment con-
sisted of both abdominal radiotherapy and procarbazine; 
however, the difference with patients who had either 
procarbazine or abdominal radiotherapy was not statis-
tically significant. These associations remained after ad-
justments for common risk factors of advanced neoplasia 
in the general population, such as smoking and a family 
history of CRC.22,24
Recent literature and recent guidelines of both the 
European Society of Gastrointestinal Endoscopy and the 
US Multi-Society Task Force on Colorectal Cancer ac-
knowledge that similarly to advanced adenomas, serrated 
lesions that have dysplasia and/or are at least 10 mm in 
size should be approached as high-risk lesions.14,17-19 We, 
therefore, now include advanced serrated lesions within 
the definition of advanced colorectal neoplasia.16,20
The current Dutch CRC screening program with 
biennial fecal immunochemical testing has insufficient 
sensitivity for advanced adenomas and especially for ad-
vanced serrated lesions for this high-risk group.25,26 Based 
on the results of this interim analysis, sufficient evidence 
is provided to currently consider a colonoscopy surveil-
lance program for HL survivors. Detailed eligibility crite-
ria for a surveillance program cannot be derived from our 
results; however, some suggestions, based on upper and 
lower limits of increased risks of advanced neoplasia, may 
aid implementation in the clinic. Previous studies from 
our own group and others suggest that there is no evi-
dence for starting surveillance sooner than 8 to 10 years 
after HL treatment because the increase in CRC risk 
starts approximately 10 to 15 years after treatment.3-5,9 
Because HL survivors have an increased risk of advanced 
colorectal neoplasia from the age of 40 years and CRC 
risk is especially increased in HL patients treated before 
the age of 35 years, we recommend that surveillance start 
not later than the age of 40 years.9 In the current study, 
TABLE 3. Logistic Regression Models for the Prevalence of Neoplasia in Hodgkin Lymphoma Treatment 
Groups Versus General Population Controls
OR (95% CI)
Advanced Adenomaa Advanced Serrated Lesionb Advanced Neoplasiac
Univariate
Treatment category
Control population (n = 1426) 1.0 (reference) 1.0 (reference) 1.0 (reference)
Abdominal RT or procarbazine (n = 66) 1.2 (0.6-2.8) 2.9 (1.2-6.5) 2.0 (1.1-3.6)
Abdominal RT and procarbazine (n = 35) 2.6 (1.1-6.1) 4.0 (1.5-10.7) 3.4 (1.6-7.0)
Multivariate
Treatment category
Control population 1.0 (reference) 1.0 (reference) 1.0 (reference)
Abdominal RT or procarbazine 2.5 (1.0-5.9) 3.7 (1.4-9.8) 3.3 (1.6-6.6)
Abdominal RT and procarbazine 4.5 (1.8-11.2) 6.2 (2.1-18.2) 5.7 (2.6-12.6)
Age (reference <55 y)
55-59 y 2.0 (1.1-4.0) 1.3 (0.6-3.1) 1.7 (1.0-2.9)
60-64 y 2.4 (1.3-4.6) 2.7 (1.3-5.7) 2.2 (1.3-3.7)
65-69 y 2.9 (1.5-5.8) 1.4 (0.5-3.7) 2.1 (1.2-3.8)
≥70 y 3.8 (1.7-8.4) 2.7 (0.9-7.8) 3.5 (1.8-6.7)
Sex (reference male) 1.4 (0.9-2.1) 0.9 (0.5-1.5) 1.2 (0.8-1.6)
Family historyd 1.6 (1.0-2.7) 1.4 (0.7-2.8) 1.7 (1.1-2.6)
Smokinge 2.1 (1.3-3.4) 3.3 (1.9-5.9) 2.5 (1.7-3.7)
BMI, kg/m2 1.0 (1.0-1.1) 1.1 (1.0-1.1) 1.0 (1.0-1.1)
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; RT, radiotherapy.
aDefined as a conventional adenoma with a ≥10-mm diameter, a ≥25% villous component, or high-grade dysplasia.
bDefined as a serrated lesion with a ≥10-mm diameter or dysplasia.
cDefined as an advanced adenoma, an advanced serrated lesion, or colorectal cancer.
dFirst-degree relative(s) with colorectal cancer versus no first-degree relative (reference).
eCurrent smoker versus former/nonsmoker (reference).
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we did not have sufficient patient numbers to evaluate 
the prevalence of advanced colorectal neoplasia before 
the age of 40 years. Similarly to the recommendations 
for other high-risk groups such as individuals with fa-
milial CRC, we suggest a 5-year interval after a negative 
colonoscopy because we do not have any evidence yet 
to suggest that a shorter interval is indicated.26 In the 
presence of neoplasia, guidelines for colonoscopy surveil-
lance after polypectomy should be followed. However, 
further research is necessary to evaluate the preventive 
effect of surveillance colonoscopies. On the basis of these 
results, the details of the surveillance program, such as 
the interval and the starting age, should be optimized. 
The efficacy of a surveillance program in HL survivors, 
including the burden and cost-effectiveness of such a 
program, should be evaluated in future studies. Future 
studies should also evaluate the potential benefits of a 
colonoscopy surveillance program for other cancer survi-
vors who have been similarly treated.1-3
In the current study, comorbidities and prior colo-
noscopies were reasons for exclusion in 9% and 13%, 
respectively, and 33% declined participation. When 
surveillance colonoscopies are being implemented, in-
creasing the participation rate will be important, and 
this should start with increasing awareness among he-
matologists and radiation oncologists by the incorpora-
tion of this recommendation into the guideline for HL 
survivors.
In addition to the higher prevalence of colorectal 
neoplasia in HL survivors, the pattern of development 
may be different from that in the general population. 
First, neoplastic lesions were more frequently located 
in the proximal colon in HL survivors in comparison 
with controls. This includes the transverse colon, which 
is the colonic region that receives a significant irradia-
tion dose during para-aortic radiotherapy and that de-
velops a high frequency of CRCs in HL survivors.15,27 
Second, especially in female HL survivors, we detected a 
high prevalence of serrated lesions and serrated polyposis 
syndrome. The reported prevalence of serrated polypo-
sis syndrome in the general population ranges from 0% 
to 0.09%.28 Therefore, prior anticancer treatment may 
be a predisposing factor for the development of serrated 
polyposis syndrome. The explanation for why different 
types of neoplastic lesions were observed between men 
and women is unclear and deserves more study.
Finally, our group previously demonstrated het-
erogeneous molecular characteristics of therapy-related 
CRCs with a high frequency of somatic mismatch repair 
gene mutations.15 These mutations could not be associated 
with a colonic region, sex, or a specific HL treatment. We 
aim to evaluate the molecular characteristics of the neo-
plastic lesions detected in the current study to gain more 
insight into therapy-related CRC pathogenesis.
A limitation of our study concerns the comparabil-
ity of our study results with the comparison population 
because colonoscopies were performed in different time 
periods (2015-2017 for HL survivors vs 2009-2010 for 
controls). The Dutch national screening program is not a 
suitable comparison population because colonoscopies are 
performed in the fecal immunochemical test–positive pop-
ulation only. In other countries, either the CRC incidence 
is not comparable with the incidence in the Netherlands, or 
detailed data are lacking on neoplastic lesions. Therefore, 
the current comparison cohort gives the best comparison 
with the Dutch general population. In both the current 
study and the comparison population, expert endoscopists 
of (partially overlapping) participating centers performed 
high-quality colonoscopies with high-definition scopes 
with narrow-band imaging. Both studies demonstrated 
adequate cecal intubation rates, withdrawal times, and 
bowel preparation scores. Nonetheless, the endoscopic 
 identification of serrated lesions can be difficult for expert 
and nonexpert endoscopists, and this may have affected 
our results.29 Endoscopists in both studies were instructed 
to detect and remove all colonic polyps, regardless of their 
endoscopic appearance or size.21 In addition, the prev-
alence of serrated lesions in the control population was 
similar to the prevalence in other recent primary colo-
noscopy and fecal immunochemical test–based screening 
cohorts.30 These cohorts originated from 4 other European 
countries and included patients who underwent a colonos-
copy between 2009 and 2015.
Because of the relatively small number of HL sur-
vivors, the evidence provided by this study is insufficient 
for small subgroups (eg, patients treated with abdomi-
nal radiotherapy alone). Another limitation of our study 
is that we may have overestimated the overall benefit 
of colonoscopy surveillance in HL survivors because 
they have high morbidity and mortality from other dis-
eases, including cardiovascular disease and other second 
malignancies.31-33
Our results are not representative for current HL pa-
tients because HL treatment regimens have seen substan-
tial changes over the past decades, including reductions 
of radiation target volumes and doses and improvements 
in techniques. In addition, chemotherapy regimens and 
doses have been adapted. Despite these adaptations, a 
recent study showed that the risk of gastrointestinal ma-
lignancies did not appear to decrease over the treatment 
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period of 1965-2000.5 Thus, a large population of survi-
vors is currently at risk of developing second gastrointes-
tinal malignancies. Future studies should evaluate risks 
for more recently treated HL survivors.
In conclusion, HL survivors who have been treated 
with abdominal radiotherapy and/or procarbazine have 
a high prevalence of advanced colorectal neoplasia and 
serrated polyposis syndrome. In addition to the increased 
risk of CRC, the evidence provided by this interim analy-
sis indicates that colonoscopy surveillance should be con-
sidered. Although the sample size of this study precludes 
the definition of precise eligibility criteria for such a sur-
veillance program, we recommend that surveillance start 
at least 8 to 10 years after HL treatment.
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